Drugs / simnotrelvir
simnotrelvir
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT05826249 | Apr → Sep 2023 | — | Jiangsu Simcere Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05731804 | Mar → Dec 2023 | impaired renal function disease | Jiangsu Simcere Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05665647 | Dec 2022 → Jan 2023 | — | Jiangsu Simcere Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05475834 | Jul → Aug 2022 | — | Jiangsu Simcere Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05339646 | Apr → Oct 2022 | — | Jiangsu Simcere Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05369676 | May → Aug 2022 | — | Jiangsu Simcere Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05373446 | May → Oct 2022 | COVID-19 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05506176 | Aug 2022 → Jan 2023 | COVID-19 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 2/3 | NCT05373433 | May 2022 → May 2023 | COVID-19 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | simnotrelvir | “OBJECTIVES: Simnotrelvir is a small-molecule highly specific 3C-like protease inhibitor for anti-SARS-CoV-2 and was approved as a combination drug with ritonavir...” PMID 39299559 ↗ Sep 2024 |
| Known as | SIM0417 | “SIM0417 (SSD8432) is an orally administered coronavirus main proteinase (3CLpro) inhibitor with potential anti-SARS-CoV-2 activity.” PMID 37484496 ↗ Jul 2023 |
| Known as | Simnotrelvir component of xiannuoxin | ChEMBL registry synonym — accepted as the source's own label CHEMBL5570561 ↗ |
| Known as | SSD8432 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05339646 ↗ |
| Known as | SY-110 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5570561 ↗ |
| Action | Inhibit | “coronavirus main proteinase (3CLpro) inhibitor” PMID 37484496 ↗ Jul 2023 |
| Modality | Small molecule | “Simnotrelvir is a small-molecule highly specific 3C-like protease inhibitor” PMID 39299559 ↗ Sep 2024 |
| Route | Oral | “SIM0417 (SSD8432) is an orally administered coronavirus main proteinase (3CLpro) inhibitor with potential anti-SARS-CoV-2 activity.” PMID 37484496 ↗ Jul 2023 |